Stockreport

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

BeOne Medicines Ltd. - American Depositary Shares  (ONC) 
PDF Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periodsGlobal BRUKINSA (zanubru [Read more]